Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calliditas Therapeutics (CALT)
NASDAQ:CALT
RESEARCH TOOLSreports
Calliditas Therapeutics (CALT) Stock Price & Analysis
113 Followers
CALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.25 - $29.30
Previous Close$20.56
Volume726.00
Average Volume (3M)6.61K
Market Cap
$530.36M
Enterprise Value$30.77M
Total Cash (Recent Filing)kr1.25B
Total Debt (Recent Filing)kr728.82M
Price to Earnings (P/E)-12.5
Beta0.34
Next Earnings
Aug 13, 2024EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding26,836,035
10 Day Avg. Volume3,254
30 Day Avg. Volume6,606
Standard Deviation0.17
R-Squared0.19
Alpha-0.00746
Financial Highlights & Ratios
Price to Book (P/B)1.96
Price to Sales (P/S)0.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$40.92Price Target Upside106.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Calliditas Therapeutics News
PremiumCompany Announcements
Calliditas Reports Breakthrough in Cancer Trial
PremiumCompany Announcements
Calliditas Triumphs with TARPEYO’s Full FDA Approval
Ownership Overview
0.00%
Insiders
0.02% Mutual Funds
0.03% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CALT FAQ
What was Calliditas Therapeutics’s price range in the past 12 months?
Calliditas Therapeutics lowest stock price was $15.25 and its highest was $29.30 in the past 12 months.
What is Calliditas Therapeutics’s market cap?
Currently, no data Available
When is Calliditas Therapeutics’s upcoming earnings report date?
Calliditas Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is in 96 days.
How were Calliditas Therapeutics’s earnings last quarter?
Calliditas Therapeutics released its earnings results on May 07, 2024. The company reported -$0.204 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.014.
Is Calliditas Therapeutics overvalued?
According to Wall Street analysts Calliditas Therapeutics’s price is currently Undervalued.
Does Calliditas Therapeutics pay dividends?
Calliditas Therapeutics does not currently pay dividends.
What is Calliditas Therapeutics’s EPS estimate?
Calliditas Therapeutics’s EPS estimate is -$0.03.
How many shares outstanding does Calliditas Therapeutics have?
Calliditas Therapeutics has 29,790,043 shares outstanding.
What happened to Calliditas Therapeutics’s price movement after its last earnings report?
Calliditas Therapeutics reported an EPS of -$0.204 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went up 2.534%.
Which hedge fund is a major shareholder of Calliditas Therapeutics?
Currently, no hedge funds are holding shares in CALT
---
Calliditas Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.92 (106.77% Upside)
$40.92 (106.77% Upside)
Blogger Sentiment
Bullish
CALT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.36%
12-Months-Change
Fundamentals
Return on Equity
-82.38%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Company Description
Calliditas Therapeutics
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
---
CALT Company Deck
---
CALT Earnings Call
Q4 2024
0:00 / 0:00
---
CALT Stock 12 Month Forecast
Average Price Target
$40.92
▲(106.77% Upside)
Technical Analysis
Best Analysts Covering CALT
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+7.92%
reiterated a buy rating 2 months ago
Copying Jon Berggren's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +7.92% per trade.
---